2. Signaling Pathways
  3. Neuronal Signaling
  4. Amyloid-β

Amyloid-β

β-amyloid peptide; Aβ; Abeta

Amyloid-β

Related Products

PDF 1.52 MB

Amyloid-β (Aβ) denotes peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease as the main component of theamyloid plaques found in the brains of Alzheimer patients. The peptides result from the amyloid precursor protein (APP), which is being cut by certain enzymes to yield Aβ. Amyloid-β molecules can aggregate to form flexible soluble oligomers which may exist in several forms. Amyloid-β peptide is due to overproduction of Aβ and/or the failure of clearance mechanisms. Amyloid-β self-aggregates into oligomers, which can be of various sizes, and forms diffuse and neuritic plaques in the parenchyma and blood vessels. Amyloid-β oligomers and plaques are potent synaptotoxins, block proteasome function, inhibit mitochondrial activity, alter intracellular Ca2+levels and stimulate inflammatory processes. Loss of the normal physiological functions of Aβ is also thought to contribute to neuronal dysfunction.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-174272
    GSK-3β inhibitor 27
    		Inhibitor
    GSK-3β inhibitor 27 (Compound 1c) is a reversible and competitive GSK-3β inhibitor with an IC50 value of 2.2 μM. GSK-3β inhibitor 27 inhibits tau hyperphosphorylation, reduces Aβ protein aggregation and possesses metal chelation and neuroprotective potential. GSK-3β inhibitor 27 is promising for research of neurodegenerative diseases (such as Alzheimer’s disease).
    GSK-3β inhibitor 27
  • HY-147547
    SV5
    		Inhibitor
    SV5 is a potent anti-Alzheimer agent. SV5 can significantly protect SHSY-5Y cells against Aβ1-42-induced death. SV5 shows moderate antioxidant and good neuroprotective activities. SV5 shows the high stability in human plasma and the best pharmacological profile.
    SV5
  • HY-144327
    Aβ-IN-2
    		Inhibitor
    Aβ-IN-2 is a Aβ1-42 aggregation inhibitor. Aβ-IN-2 inhibits Aβ1-42 self-aggregation in vitro by delaying the exponential growth phase or reduces the quantity of fibrils in the steady state. Aβ-IN-2 can be used for the research of conformational disorders.
    Aβ-IN-2
  • HY-W657887
    GSK-3β/G9a-IN-1
    		Inhibitor
    GSK-3β/G9a-IN-1 (Compound T2) is an orally active, selective, blood-brain-barrier permeable, competitive G9a (substrate-competitive, IC50: 1.1 μM) and GSK-3β (ATP competitive, IC50: 0.8 μM) inhibitor. GSK-3β/G9a-IN-1 is a potent H3K9me2 inhibitor that reshapes chromatin landscape. GSK-3β/G9a-IN-1 lowers tau phosphorylation, reduces Aβ aggregation. GSK-3β/G9a-IN-1 displays inhibition toward glucocorticoid receptor, androgen receptor, and alpha-2A adrenergic receptor. GSK-3β/G9a-IN-1 also upregulates SAGA complex members such as Eny2 and Sgf29. GSK-3β/G9a-IN-1 markedly improves memory, restores social behaviors, and increases synaptic complexity in late-onset Alzheimer’s disease.
    GSK-3β/G9a-IN-1
  • HY-165341
    SCR1693
    		Inhibitor
    SCR1693 is a selective, reversible, orally active and noncompetitive inhibitor of AChE (IC50 = 0.68 μM) as well as a calcium channel blocker. SCR1693 reduces tau phosphorylation levels, and inhibits the generation and release of Aβ. SCR1693 restores insulin signaling and improves cognitive deficits. SCR1693 can be used for the study of Alzheimer's disease, especially which complicated with type 2 diabetes mellitus.
    SCR1693
  • HY-16633
    ELND 007
    		Inhibitor
    ELND 007 (Compound 34) is a metabolically stable γ-secretase inhibitor designed to selectively inhibit amyloid beta (Aβ) generation while minimizing Notch inhibition. Developed alongside ELND 006 (Compound 30), it underwent human clinical trials following a synthetic strategy emphasizing diversity and chirality. In preclinical studies, ELND 007 showed promising in vitro and in vivo characteristics, effectively reducing Aβ levels. Comparative studies with other γ-secretase inhibitors like Semagacestat, Begacestat, and Avagacestat highlighted its efficacy in lowering Aβ production, particularly demonstrated by reduced Aβ levels in the cerebrospinal fluid (CSF) of healthy human volunteers, suggesting potential therapeutic benefit for Alzheimer's disease.
    ELND 007
  • HY-120449
    AZ4800
    		Inhibitor
    AZ4800 is a combined inhibitor of two targets in the amyloid precursor protein processing process with additive lowering activity on Aβ42 levels in vitro and in vivo.
    AZ4800
  • HY-N0602R
    Ginsenoside Rg2 (Standard)
    		Inhibitor
    Ginsenoside Rg2 (Standard) is the analytical standard of Ginsenoside Rg2. This product is intended for research and analytical applications. Ginsenoside Rg2 is one of the major active components of ginseng. Ginsenoside Rg2 inhibits VCAM-1 and ICAM-1 expressions stimulated with lipopolysaccharide (LPS). Ginsenoside Rg2 also reduces Aβ1-42 accumulation.
    Ginsenoside Rg2 (Standard)
  • HY-114239
    JBPOS-0101
    		Inhibitor
    JBPOS-0101 is a phenyl carbamate compound. JBPOS-0101 exhibits neuroprotective and antiepileptic effects. JBPOS-0101 can attenuate the accumulation of Aβ in 5XFAD mouse brains and rescue the deficits in learning and memory. JBPOS-0101 can be used for the research of neurological disease, such as Alzheimer's disease (AD).
    JBPOS-0101
  • HY-157978
    AChE-IN-59
    		Inhibitor
    AChE-IN-59 (compounds 3b) is an AChE inhibitor, with an IC50 value of 0.05 μM. AChE-IN-59 can inhibit the aggregation of Aβ1-42, protect nerve cells and penetrate the blood-brain barrier well. AChE-IN-59 can be used for the research of Alzheimer's disease (AD).
    AChE-IN-59
  • HY-114234
    TAK-070 hydrochloride hydrate
    		Inhibitor
    TAK-070 hydrochloride hydrate is a noncompetitive and orally active BACE1 inhibitor (IC50 = 3.15 μM). TAK-070 hydrochloride hydrate can be used for research of Alzheimer’s disease (AD). TAK-070 hydrochloride hydrate inhibits brain levels of soluble Aβ, and improves cognitive impairments in AD model.
    TAK-070 hydrochloride hydrate
  • HY-119292
    AP2238
    		Inhibitor
    AP2238 is a dual-function acetylcholinesterase (AChE) inhibitor with Ki values for human AChE (HuAChE) and butyrylcholinesterase (BuChE) of 21.7 and 48.9 μM respectively. AP2238 blocks the pro-fibrotic interaction between the peripheral site of AChE and Aβ, and can inhibit Aβ aggregation. AP2238 can be used for the research of Alzheimer's disease.
    AP2238
  • HY-W011727AR
    Pyridoxal 5'-phosphate monohydrate (Standard)
    		Inhibitor
    Pyridoxal 5'-​phosphate (monohydrate) (Standard) is the analytical standard of Pyridoxal 5'-​phosphate (monohydrate). This product is intended for research and analytical applications. Pyridoxal 5'-phosphate monohydrate, the active form of vitamin B6, is an essential cofactor for multiple enzymes, including aromatic l-amino acid decarboxylase that catalyzes the final stage in the production of the neurotransmitters dopamine and serotonin. Pyridoxal 5'-phosphate monohydrate is the most important coenzyme variant in the process of vitamin B6 intracellular phosphorylation and is interconvertible with other variants, including pyridoxine 5′‐phosphate (PNP) and pyridoxamine 5′-phosphate (PMP).
    Pyridoxal 5'-phosphate monohydrate (Standard)
  • HY-117710B
    AD-35
    		Inhibitor
    AD-35 is an orally active anti-Alzheimer's disease (AD) agent with moderate AChE inhibitory activity and metal ion chelating ability. AD-35 exhibits IC50 values for AChE and BuChE of 793 nM and 31428 nM, respectively. AD-35 can form chelates with Cu²⁺ and Fe³⁺, but its chelating ability for Zn²⁺ is relatively weak. AD-35 can inhibit Aβ aggregation and disassemble the formed Aβ aggregates, and inhibit Aβ-induced ERK phosphorylation. AD-35 inhibits neuroinflammation in AD rat models and demonstrates a strong effect in improving cognitive function.
    AD-35
  • HY-163655
    Glutaminyl Cyclase Inhibitor 6
    		Inhibitor
    Glutaminyl Cyclase Inhibitor 6 (compound BI-43) is a secretory glutaminyl cyclase (sQC) and golgi-resident glutaminyl cyclase (gQC) inhibitor with IC50 values of 0.012 0.040 µM, respectively. Glutaminyl Cyclase Inhibitor 6 has the potential for the research of Parkinson’s disease.
    Glutaminyl Cyclase Inhibitor 6
  • HY-P10630
    Pep63
    		Inhibitor
    Pep63 is a neuroprotective peptide (VFQVRARTVA). Pep63 has a neuroprotective effect on synaptic plasticity and memory. Pep63 can competitively bind with Aβ1-42 oligomers, and can block Aβ fiber formation. Pep63 can be used for Alzheimer’s disease (AD) research.
    Pep63
  • HY-162832
    Amyloid-β-IN-1
    		Inhibitor
    Amyloid-β-IN-1 (compound 13) is a synthetic peptide containing the hydrophobic C-terminal region "VVIA-NH2" and its reverse sequence "AIVV-NH2" of Aβ42, which is an Aβ inhibitor. Amyloid-β-IN-1 can inhibit Aβ aggregation and has neuroprotective effects.
    Amyloid-β-IN-1
  • HY-W740884
    Rutin-d3
    		Inhibitor
    Rutin-d3 is a deuterated labeled Rutin-d3.
    Rutin-d<sub>3</sub>
  • HY-N0603R
    20(S)-Ginsenoside Rg3 (Standard)
    		Inhibitor
    20(S)-Ginsenoside Rg3 (Standard) is the analytical standard of 20(S)-Ginsenoside Rg3. This product is intended for research and analytical applications. 20(S)-Ginsenoside Rg3 is the main component of Panax ginseng C. A. Meyer. Ginsenoside Rg3 inhibits Na+ and hKv1.4 channel with IC50s of 32.2±4.5 and 32.6±2.2 μM, respectively. 20(S)-Ginsenoside Rg3 also inhibits Aβ levels, NF-κB activity, and COX-2 expression.
    20(S)-Ginsenoside Rg3 (Standard)
  • HY-17406R
    Tolcapone (Standard)
    		Inhibitor
    Tolcapone (Standard) (Ro 40-7592 (Standard)) is the analytical standard of Tolcapone (HY-17406). Tolcapone (Ro 40-7592) is a selective, potent and orally active COMT inhibitor with an IC50of 773 nM. Tolcapone can inhibits α-syn and Aβ42 oligomerization and fibrillogenesis. Tolcapone can cause oxidative stress and induce cancer cells apoptosis and ROS production. Tolcapone can be used for the researches of cancer and neurological disease, such as Parkinson disease and neuroblastoma.
    Tolcapone (Standard)
Cat. No. Product Name / Synonyms Application Reactivity